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The autophagy initiator ULK1 sensitizes AMPK to
allosteric drugs
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AMP-activated protein kinase (AMPK) is a metabolic stress-sensing enzyme responsible for
maintaining cellular energy homeostasis. Activation of AMPK by salicylate and the thieno-
pyridone A-769662 is critically dependent on phosphorylation of Ser108 in the β1 regulatory
subunit. Here, we show a possible role for Ser108 phosphorylation in cell cycle regulation and
promotion of pro-survival pathways in response to energy stress. We identify the autophagy
initiator Unc-51-like kinase 1 (ULK1) as a β1-Ser108 kinase in cells. Cellular β1-Ser108 phos-
phorylation by ULK1 was dependent on AMPK β-subunit myristoylation, metabolic stress
associated with elevated AMP/ATP ratio, and the intrinsic energy sensing capacity of AMPK;
features consistent with an AMP-induced myristoyl switch mechanism. We further
demonstrate cellular AMPK signaling independent of activation loop Thr172 phosphorylation,
providing potential insight into physiological roles for Ser108 phosphorylation. These ﬁndings
uncover new mechanisms by which AMPK could potentially maintain cellular energy
homeostasis independently of Thr172 phosphorylation.
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The evolutionarily conserved AMP-activated protein kinase(AMPK) is a key regulator of cellular and whole-bodyenergy homeostasis that controls multiple branches of
metabolism to redress energy imbalances caused by physiological
and pathological processes1, 2. AMPK senses increased cellular
AMP/ATP ratio during periods of energy stress (hypoxia, nutri-
ent deprivation, exercise) and protects the cell from these events
by switching off energy-consuming anabolic pathways and
switching on catabolic pathways to restore ATP levels. Multiple
physiological processes are regulated by AMPK including autop-
hagy, appetite control, mitochondrial biogenesis and cell growth,
and proliferation. Consequently, extensive efforts have been made
to develop AMPK-activating drugs for potential therapeutic use in
treating metabolic diseases (type 2 diabetes, obesity, cardiovascular
disease) and also cancer and inﬂammatory diseases.
The AMPK αβγ heterotrimer comprises an α-catalytic subunit
and regulatory β- and γ-subunits. Multiple isoforms of each
subunit exist in mammals (α1/2, β1/2, γ1/2/3) and isoform-
speciﬁc variations in tissue distribution, regulation, and function
have been demonstrated. Both β-isoforms contain a
carbohydrate-binding module (CBM) and are myristoylated at
position Gly2, a modiﬁcation that targets AMPK to intracellular
membranes and is important for temporospatial regulation of
AMPK signaling3, 4. γ-subunits possess three allosteric adenylate
nucleotide-binding sites that bind ATP, ADP and AMP inter-
changeably, enabling AMPK to sense ﬂuctuations in cellular
energy state5–7.
In most instances, ligand-induced allosteric regulation of
AMPK is governed by distinct phosphorylation events that either
sensitize AMPK to nucleotides/drugs binding at γ-subunit sites
(phosphorylation of Thr172 (pThr172) in the α-subunit activa-
tion loop8–10), or small compounds binding at the ADaM
(allosteric drug and metabolism) site (phosphorylation of
β-Ser108 (pSer108) in the β-CBM11–13). An exception is syner-
gistic activation of unphosphorylated AMPK when γ- and ADaM
sites are occupied simultaneously10, 13. The ADaM site, a largely
hydrophobic cavity formed between the α-kinase domain small
lobe and β-subunit CBM, was identiﬁed in crystal structures of
AMPK/drug complexes12, 14. These structures revealed that the
phosphate group of pSer108 forms electrostatic interactions with
α2-kinase domain residues Thr21, Lys31, and Lys33, thereby
stabilizing the ADaM site and explaining the role of pSer108 in
mediating drug sensitization. The precise mechanism by which
ADaM site drugs activate AMPK is not fully understood. pSer108
is absolutely required for AMPK activation by A-76966211, 13,
salicylate15 and MT47-10016, and increases by 40-fold potency of
the high afﬁnity drug 99112. Using puriﬁed enzyme we further
demonstrated that activation loop phosphorylation is dispensable
for AMPK stimulation by A-76966214. The well-deﬁned character
of the AMPK drug site, and its regulation through reversible
phosphorylation, has led to speculation that synthetic activators
(991, A-769662) and salicylate are mimicking an endogenous
metabolite(s) that would be capable of sustaining AMPK signal-
ing in the absence of pThr1721, 17.
Thr172 phosphorylation is considered a marker of AMPK
activity; identiﬁcation of upstream kinases, and the mechanisms
underpinning pThr172 regulation, have been the subject of
intense investigation over several decades. LKB1 and CaMKK2
(Ca2+/calmodulin-dependent protein kinase kinase 2) have been
identiﬁed as in vivo Thr172 kinases18. Despite some conﬂicting
evidence, current models of AMPK regulation by adenine
nucleotides describe a tripartite mechanism in which ATP
exchange for AMP and ADP at γ-sites (i) promotes Thr172
phosphorylation, (ii) suppresses pThr172 dephosphorylation, and
(iii) (for AMP) allosterically activates Thr172-phosphorylated
AMPK3, 5, 6. Hierarchical phosphorylation events in the
α-subunit Ser/Thr rich ST-loop (human α1(472–525)) have also
been reported to negatively regulate pThr172, either by sup-
pressing Thr172 phosphorylation (α-Ser487 auto-, Akt- or PKA-
phosphorylation1, 2), or by promoting pThr172 depho-
sphorylation (α-Thr479 phosphorylation by GSK319). Activity of
the autophagy initiator Unc-51-like kinase (ULK), itself an
AMPK substrate, is associated with reduced pThr172 via an
uncharacterized negative feedback loop20.
In contrast, regulation and function of β-Ser108 phosphor-
ylation have been largely unexplored. Ser108 is highly conserved
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Fig. 1 A-769662 activation of cellular AMPK signaling is dependent on β1-pSer108. a Reconstitution of basal AMPK signaling in AMPK β1/2 double
knockout (β1/2-dKO) iMEFs by lentiviral transduction of AMPK β1 WT or S108A mutant. b Immunoblots for pACC from β1/2-dKO iMEFs-expressing β1 WT
or S108A mutant, stimulated with 20 μM A-769662 for 90min. n= 3. Error bars, mean pACC fold change relative to basal± s.e.m. Statistical analysis was
performed using unpaired two-tailed Student’s t-test. **P< 0.01 indicates signiﬁcant increase in pACC compared to basal
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in eukaryotes and was identiﬁed as an autophosphorylation site in
rat liver AMPK preparations21. Closer examination using kinase
inactive (KI) AMPK expressed in COS-7 cells revealed that
Ser108 is a cis-autophosphorylation site (dependent on intra-
molecular Thr172 phosphorylation) that is dephosphorylated
following removal of the AMPK-activating stimulus. Thus, as for
Thr172, Ser108 is largely unphosphorylated under basal condi-
tions13. Identiﬁcation of alternate upstream kinases for Ser108
would provide advances in two important areas: ﬁrstly, char-
acterization of novel Ser108 kinases implicates their therapeutic
modulation as a strategy to increase potency of AMPK-targeting
drugs; secondly, feed-forward regulation by Ser108 kinases might
denote the cellular processes under which concentrations of
natural AMPK ligands become elevated. Here, we demonstrate
that AMPK β1-Ser108 is a substrate for ULK1 under conditions
associated with elevated AMP. We also provide unambiguous
demonstration of AMPK signaling independently of Thr172
phosphorylation. These ﬁndings underpin a ULK-mediated
“ligand switch” model of AMPK allosteric control, in which the
adenylate charge-sensing role of β1-AMPK is replaced by an
ability to detect perturbations in endogenous metabolite(s) acting
at the ADaM site.
Results
β1-pSer108 confers cellular AMPK drug sensitivity. The
importance of Ser108 phosphorylation in sensitizing AMPK to
ADaM site ligands has been well-characterized using puriﬁed
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Fig. 2 Quantitative global and phosphoproteomic analysis uncovers cellular roles for β1-pSer108. a Representative immunoblots for β1/2-dKO
iMEFs-expressing β1 mutants S108A or S108E, stimulated with 2mM phenformin for 1 h. b Workﬂow showing the stable isotope dimethyl labeling-based
quantitative proteomic and phosphoproteomic approach. c Heatmap showing signiﬁcantly perturbed cellular phosphoproteins and corresponding
phosphosites. Red indicates increased, and green decreased, phosphorylation in β1-S108E compared to β1-S108A-expressing cells. Gray indicates missing
phosphopeptide in that replicate. d Immunoblot/densitometry analysis conﬁrming increased PAK2-Ser141 phosphorylation in β1-S108E-expressing cells.
n= 3, representative immunoblot is shown. Error bars, mean PAK2-Ser141 phosphorylation (arbitrary units)± s.e.m. Statistical analysis was performed
using unpaired two-tailed Student’s t-test. *P< 0.05 indicates signiﬁcant increase in PAK2-pSer141 in S108E-expressing cells compared to S108A-
expressing cells. e ‘‘Cell cycle, connective tissue development and function, cellular movement’’ is one of the top networks associated with changes in
phosphoproteome between S108A and S108E-expressing iMEFs, as identiﬁed by Ingenuity Pathway Analysis software
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AMPK enzyme in vitro, but whether this translates to cellular
AMPK signaling has not been unequivocally demonstrated. To
exclude signaling from endogenous AMPK we generated an
immortalized mouse embryonic ﬁbroblast (iMEF) cell line
derived from mouse embryos harboring genetic deletion of both
β1 and β2 isoforms22 (β1/2-dKO). As expected, β1/2-dKO iMEFs
were devoid of detectable AMPK α- or β-subunit expression and
AMPK signaling as evidenced by lack of phosphorylation of the
AMPK substrate ACC-Ser79 (Fig. 1a). Lentiviral-transduction of
either FLAG-tagged wild-type (WT) or S108A mutant β1 in β1/2-
dKO iMEFs reconstituted expression of AMP-sensitive AMPK
heterotrimers, and recovered phenformin-sensitive AMPK sig-
naling in transduced cells (Fig. 1a and Supplementary Fig. 1a, b).
Incubation with the direct AMPK agonist A-769662 (20 μM) led
to a signiﬁcant increase (1.9-fold) in pACC-Ser79 in β1/2-dKO
iMEFs-expressing WT β1, but not the β1 S108A mutant (Fig. 1b).
A-769662-stimulation was mediated exclusively through the
ADaM site, since phosphorylation of Thr172 was not increased at
this dose (Supplementary Fig. 1c). These results conﬁrm a
requirement for Ser108 phosphorylation in drug activation of
AMPK in cells.
Phosphoproteomic analysis hints at roles for β1-pSer108. To
investigate the cellular fate of β1-Ser108 phosphorylation, we
performed a stable isotope dimethyl labeled-based quantitative
proteomic and phosphoproteomic analysis using β1/2-dKO
iMEFs, transduced with either β1 mutant S108A or S108E
(Fig. 2a). We previously showed that Glu at position 108 acts as
an effective phosphomimetic, with regard sensitizing AMPK to
activation by A-76966213. Following 1 h phenformin (2 mM)
treatment, β1 S108A and S108E transduced iMEF lysates were
compared to trace out the changes in proteome and phospho-
proteome (Fig. 2b). Fifteen cellular phosphoproteins showed
signiﬁcant changes in phosphorylation between S108A and
S108E-expressing cells in our study (Fig. 2c, Supplementary
Table 1) with no detectable differences in AMPK expression or
phenformin-induced Thr172 phosphorylation (Fig. 2a, Supple-
mentary Fig. 2a). For example, we identiﬁed increased phos-
phorylation of p21-activated kinase 2 (PAK2) on Ser141/Ser152,
located in the kinase inhibitory domain, in phenformin-treated
iMEFs-expressing β1 S108E, whereas global proteome data
showed no changes in PAK2 protein level (Supplementary
Fig. 2b, c). Immunoblot analysis with a phosphospeciﬁc antibody
conﬁrmed signiﬁcant increase in pPAK2-Ser141 in S108E-
expressing cells, validating our representative phosphoproteome
data (Fig. 2d). Collectively, pathway and network analysis using
ingenuity pathway analysis (IPA) identiﬁed ‘‘Cell cycle, con-
nective tissue development and function, cellular movement’’ as
a
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Fig. 3 β1-Ser108 trans-phosphorylation occurs via an AMPK independent mechanism. a Rationale for employing kinase inactive (KI) AMPK to examine
cellular Ser108 phosphorylation. β1-Ser108 phosphorylation (blue) can potentially be performed by an upstream kinase in both WT and KI α1(D141A)
AMPK mutant. LKB1/CaMKK2-mediated phosphorylation of α-Thr172 (red) activates WT AMPK (orange) leading to background Ser108
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KI-α1β1γ1 puriﬁed from HEK293T cells treated with AMPK-activating agents/conditions: glucose free (glucose-free DMEM+ 10% serum, 4 h), AICAR
(2mM, 1 h), H2O2 (1 mM, 45min), A-769662 (300 μM, 1 h), phenformin (2 mM, 1 h), ionomycin (2.5 μM, 15 min) and amino-acid free (EBSS medium, 4 h).
n= 3, representative immunoblots shown. C: Bacterial expressed, CaMKK2-treated α1β1γ1 standard. c Reconstitution of basal AMPK signaling in AMPK
α1/2 double knockout (α1/2-dKO) iMEFs by lentiviral transduction of AMPK α1 WT, but not the KI mutant. d Immunoblot for β1-pSer108 from α1/2-dKO
iMEFs-expressing KI-α1, stimulated with 2 mM phenformin for 1 h. n= 3, representative immunoblots shown
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one of the top networks associated with these perturbed cellular
phosphoproteins (Fig. 2e).
β1-Ser108 can be phosphorylated in trans. We previously
demonstrated that AMPK β1-Ser108 is cis-autophosphorylated
via an intramolecular mechanism reliant on prior phosphoryla-
tion of α-Thr17213. This implies that, in the absence of alternate
signaling, aberrant phosphatase regulation or conditions leading
to trans-autophosphorylation, stoichiometries of pSer108 and
pThr172 are intrinsically linked and, for the most part, equiva-
lent. To interrogate this model we screened AMPK-activating
conditions/agents under which Ser108 becomes a substrate for a
trans-phosphorylation event in cells. To prevent background cis-
signaling we expressed a GST-fusion of the KI AMPK mutant α1
(D141A)β1γ1 in HEK293T cells. This complex is a suitable
substrate for Thr172-phosphorylating kinases LKB1 and
CaMKK2, but does not undergo Ser108 cis-autophosphorylation
(Fig. 3a). Glucose starvation, or incubation with H2O2 or phen-
formin, each induced phosphorylation at Ser108 (Fig. 3b). Incu-
bation with ionomycin (activator of CaMKK2 signaling), AICAR
(5-aminoimidazole-4-carboxamide ribonucleotide) or A-769662,
or amino-acid deprivation, each failed to elicit Ser108 phos-
phorylation at the single experimental time point used. We used
α1/2-dKO iMEFs23 to exclude the possibility that Ser108 is trans-
autophosphorylated in phenformin-treated cells. Lentiviral-
transduction of α1/2-dKO iMEFs with FLAG-tagged WT- or
KI-α1 reconstituted AMPK expression; as expected only WT α1
transduction recovered AMPK signaling (Fig. 3c). However,
phenformin induced phosphorylation of Ser108 in α1/2-dKO
iMEFs transduced with KI-α1, which was not increased by
additional incubation with 100 μM A-769662 (Fig. 3d). Our
results demonstrate that, under certain metabolic stress condi-
tions, Ser108 is a substrate for a kinase(s) other than AMPK
autophosphorylation.
ULK1 phosphorylation of β1-Ser108 induces drug sensitivity.
To identify upstream kinases for β1-Ser108 we screened a syn-
thetic peptide corresponding to AMPK β1(102–114) (S108tide)
(Fig. 4a) against a panel of 284 Ser/Thr kinases. 92% of the
kinases screened yielded low activities against S108tide (<10% vs.
top hit). Several kinases from diverse groups demonstrated
comparable (>35%) speciﬁc activity relative to AMPK α1β1γ1,
e.g., BRSK1/2, NEK2/9, TAOK1 (Supplementary Table 2).
Among positive hits was ULK1, which is in accordance with
identity of the sequence surrounding β1-Ser108 to the consensus
motif for substrates of this kinase24, particularly Leu, Thr, and
Arg directly N-terminal to Ser108 (positions P-3, P-2, and P-1,
respectively) (Fig. 4a). We performed a more detailed analysis
and phosphorylated the S108tide substrate using puriﬁed FLAG-
ULK1, either alone (kcat/Km 1.23 × 10−2/s/μM) or complexed to
interaction partners FIP200 and Atg13 (kcat/Km 1.86 × 10−3/s/
μM) (Fig. 4b and Supplementary Fig. 3a). ULK2 demonstrated
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reduced efﬁciency in phosphorylating S108tide (kcat/Km
2.63 × 10−4/s/μM), compared to ULK1 (Fig. 4b). We examined
ULK phosphorylation of the AMPK heterotrimer using puriﬁed
KI-α1β1γ1 expressed in bacteria, since we previously found the
WT complex extracted from this source is autophosphorylated at
β1-Ser108 with ~ 60% stoichiometry despite lacking pThr17213.
ULK1 phosphorylated β1-Ser108, but not α1-Thr172, in
KI-AMPK, whereas we did not detect phosphorylation of either
residue by ULK2 (Fig. 4c). MS/MS analysis conﬁrmed
ULK1-phosphorylation of Ser108 in KI-α1β1γ1 (Supplementary
Fig. 3b, c).
We found that expression of the mutant α1(C176S)β1γ1 in
bacteria produced AMPK that was devoid of pSer108 (Supple-
mentary Fig. 3d) yet retained full allosteric regulatory mechan-
isms, such as A-769662/AMP and A-769662/C2 synergistic
activation (Supplementary Fig. 3e)10, 13, or individual A-769662
(Supplementary Fig. 3f) and AMP (Supplementary Fig. 3g)
activation following phosphorylation by CaMKK2. One explana-
tion is that pThr172-independent basal activity, and hence Ser108
autophosphorylation, is induced by modiﬁcation of Cys176 in the
activation loop, occurring as a result of oxidative stress during
AMPK expression in bacteria. Redox sensitive mechanisms are
known to regulate receptor tyrosine kinases25 and a variety of
Ser/Thr kinases including CaMK2, PKA and PKC26–28. The α1
(C176S)β1γ1 construct allowed us to investigate the effect of ULK
phosphorylation on ligand-mediated regulation of AMPK with-
out the need for prior and extensive phosphatase treatment. We
found that ULK pre-treatment sensitized puriﬁed AMPK α1
(C176S)β1γ1 to activation by A-769662 or salicylate (Fig. 4d). We
detected ULK1-phosphorylation at several other AMPK α1, β1,
and γ1 sites (Supplementary Fig. 3c). These included γ1 residues
Ser261 and Ser270, located in proximity to nucleotide site 3,
which is important for AMP allosteric regulation3, 7. However,
AMP allosteric activation of WT α1β1γ1 was not signiﬁcantly
affected by pre-treatment with ULK1 (Supplementary Fig. 3g).
ULK1 phosphorylation of β-Ser108 is speciﬁc to AMPK β1.
Ser108 is conserved between mammalian AMPK β-isoforms 1
and 2, however identity of the β2 sequence to the ULK consensus/
favored motif is restricted to Leu at P-3 (Fig. 4a). ULK1 was
previously shown to phosphorylate multiple AMPK β2 residues
in vitro, but not Ser10820. To conﬁrm β-isoform speciﬁcity of
ULK1 we generated a phosphospeciﬁc antibody to β2-pSer108
(Supplementary Fig. 4). Incubation of WT α1β1γ1 or α1β2γ1 with
CaMKK2 resulted in Thr172 phosphorylation and subsequent
Ser108 autophosphorylation (Fig. 5a). ULK1 treatment of
KI-α1β2γ1 resulted in reduced electrophoretic migration of β2,
indicative of multiple phosphorylation events. However, we did
not detect β2-pSer108 by immunoblot following ULK1 treatment
(Fig. 5a, right panel). Furthermore, exposure of HEK293T cells to
H2O2 failed to induce Ser108 phosphorylation in KI-α1β2γ1
(Fig. 5b, right panel).
β1-Ser108 is a cellular substrate for ULK. We examined whether
ULK phosphorylates β1-Ser108 in HEK293T cells. Initially, we
used the highly selective, ULK1 small molecule inhibitor
SBI-0206965 (termed 6965)24. We found that pre-incubation of
transfected HEK293T cells with 10 μM 6965, a concentration
previously shown to have no effect on AMPK signaling24, sig-
niﬁcantly reduced H2O2- (Fig. 6a) and phenformin- (Fig. 6b)
induced phosphorylation of Ser108 in KI-AMPK α1β1γ1, relative
to 6965 untreated cells. Treatment with 6965 caused a signiﬁcant
increase in pThr172 in KI-α1β1γ1 in response to both H2O2 and
phenformin (Fig. 6a, b); this is consistent with a role for ULK1 as
a negative regulator of Thr172 phosphorylation.
We investigated regulation of Ser108 phosphorylation in
iMEFs in which both ULK1 and ULK2 had been genetically
deleted (ulk1/2-dKO)29 (Supplementary Fig. 5). Under basal
conditions, pSer108 in endogenous AMPK was signiﬁcantly
higher in both WT and ulk1/2-dKO iMEFs compared to
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HEK293T cells, despite no detectable increase in pThr172
(Fig. 6c). We bypassed this high basal signal in iMEFs by
examining pSer108 in KI-AMPK, expressed by lentiviral
transduction of a FLAG-tagged KI-α1(D141A) mutant and
isolated with endogenous β- and γ-subunits by FLAG
immunoprecipitation. KI-AMPK expressed in iMEFs was devoid
of basal pSer108 (Fig. 6d). Phenformin-induced phosphorylation
of Ser108 was signiﬁcantly decreased (>90%) in KI-AMPK from
ulk1/2-dKO iMEFs, compared to WT iMEFs (Fig. 6d). Combined,
these results conﬁrm β1-Ser108 as a cellular substrate for ULK1.
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An AMP myristoyl switch triggers β1-Ser108 trans-
phosphorylation. H2O2 and phenformin indirectly activate
AMPK through perturbation of adenine nucleotide ratios
(increased AMP/ATP ratio, reduced adenylate charge). We found
that H2O2 and phenformin treatments of HEK293T cells that
induced Ser108 phosphorylation (Fig. 3b) also produced sig-
niﬁcant falls in adenylate energy charge (AEC), with H2O2 incu-
bation having the greater effect (AMP/ATP ratios: basal 0.0093±
0.0015; phenformin 0.0177± 0.0041; H2O2 0.0418± 0.0033)
(Fig. 7a). Therefore, we investigated whether elevated AMP was a
requirement for phosphorylation of Ser108 by ULK1. Phenformin
treatment of HEK293T cells failed to induce Ser108 phosphor-
ylation in KI-α1β1γ1 carrying a mutation in the γ1 nucleotide site
3 (γ1-D245A) that renders AMPK insensitive to stimulation by
AMP3 (Fig. 7b). ULK1 can also be activated in response to small
molecule mTOR inhibitors (AZD8055, INK128) that suppress
mTOR-mediated phosphorylation at the ULK1 inhibitory site
Ser75724. Incubation of HEK293T cells with 1 μM AZD8055 or
INK128 induced almost complete loss of ULK-pSer757, without
signiﬁcantly affecting adenylate charge or stimulating phosphor-
ylation of Ser108 in KI-α1β1γ1 expressed in these cells (Fig. 7a, c).
These data indicate that ULK1 phosphorylation of β1-Ser108 in
cells requires a reduction in adenylate charge and is dependent on
the AMP-sensing abilities of AMPK.
N-terminal myristoylation of β-Gly2 plays important roles in
AMPK temporospatial regulation, being required for AMP-
stimulation of Thr172 phosphorylation by upstream kinases and
metabolic stress-induced co-localization of AMPK to both
b
α-pT172
β1-pS108
β1
HEK293T:GST pulldown
Phenformin:
WT D245Aγ1:
Ad
en
yla
te
 e
ne
rg
y 
ch
ar
ge
0.98
0.94
0.90
0.86
0.92
0.88
0.96
a
*
****
0.84
Ba
sa
l
Ph
en
for
mi
n
H 2
O 2
AZ
D8
05
5
INK
12
8
100
kD
100
37
37
– + – +
HEK293T:GST pulldown
β1:
–
– –
+–+
++
d
myr Non-myr
Phenformin:
Glucose:
β1-pS108
β1
β1-pS108
β1
37
kD
37
37
37
β1-pS108
β1
C Non-myr myr
ULK1:
AMP:
–
––––
– +
+
+
+
+ +
37
kD
37
75
75α
c HEK293T
lys
at
e
AZD8055:
C
INK128:
ULK1-pS757
Tubulin
α-pT172
β1-pS108
β1 G
ST
 
pu
lld
ow
n
150
kD
–
– – – +
––+
50
37
37
100
75
75
100
α
e Basal
AMP
pS
er
10
8/
β1
(ar
bit
rar
y u
nit
s)
0
3
2
1
Non-myr
Purified α1β1γ1
***
myr
Fig. 7 An AMP-myristoyl switch triggers ULK1 phosphorylation of β1-Ser108. a Adenine nucleotides extracted from HEK293T cells incubated with
phenformin (2 mM, 1 h), H2O2 (1 mM, 45min), AZD8055 (1 μM, 1 h), or INK128 (1 μM, 1 h) were quantitated by mass spectrometry. Adenylate energy
charge was calculated as described in Online Methods. n= 3. Error bars, mean adenylate energy charge± s.e.m. Statistical analyses were performed using
one-way ANOVA with post hoc Dunnett’s multiple comparison test. ****P> 0.001, *P< 0.05 indicate signiﬁcant decrease in mean adenylate energy
charge compared to basal. b Immunoblots for β1-pSer108 and α-pThr172 in KI-α1β1γ1 or KI-α1β1γ1(D245A) puriﬁed from HEK293T cells stimulated with
2mM phenformin for 1 h. n= 3, representative immunoblots shown. c Immunoblots for ULK1-pSer757, and β1-pSer108 and α-pThr172 in KI-α1β1γ1 puriﬁed
from HEK293T cells incubated with 1 μM mTOR inhibitors AZD8055 or INK128 for 1 h. n= 3, representative immunoblots shown. C: Bacterial expressed,
CaMKK2-treated α1β1γ1 standard. d Immunoblots for β1-pSer108 in KI-α1β1γ1 (myr) or KI-α1β1(G2A)γ1 (non-myr) puriﬁed from HEK293T cells incubated
with 2mM phenformin for 1 h (upper) or glucose free medium for 4 h (lower). n= 3, representative immunoblots shown. e Immunoblot for β1-pSer108 in
bacterial-expressed, non-myristoylated (non-myr) or myristoylated (myr) KI-α1β1γ1 phosphorylated with ULK1 for 30min in the presence of 100 μM AMP.
n= 3, representative immunoblots shown. C: CaMKK2-treated α1β1γ1 standard. Error bars, mean increase in β1-pSer108 relative to ULK1-untreated± s.e.m.
Statistical analysis was performed using unpaired two-tailed Student’s t-test. ***P< 0.001 indicates signiﬁcant decrease in β1-pSer108 relative to
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upstream kinases and protein targets located at intracellular
membranes3, 30, 31. We examined the requirement for β-
myristoylation in directing Ser108 phosphorylation during
cellular metabolic stress. We found that KI-α1β1γ1 containing a
myristoylation-deﬁcient β1-G2A mutant (non-myr) was insensi-
tive to phenformin- or glucose starvation-induced phosphoryla-
tion of Ser108 in HEK293T cells (Fig. 7d). We examined the effect
of β-myristoylation on cell-free ULK1-phosphorylation of Ser108
using myristoylated and non-myristoylated forms of KI-α1β1γ1.
In contrast to our observation in cells, β-myristoylation resulted
in signiﬁcant suppression of ULK1-mediated Ser108 phosphor-
ylation, which was not relieved by addition of AMP (Fig. 7e).
pThr172 is not absolutely required for AMPK signaling. To
assess whether AMPK cellular signaling can be triggered inde-
pendently of Thr172 phosphorylation, we expressed FLAG-
tagged α2 WT or T172A mutant in α1/2-dKO iMEFs at similar
levels (Fig. 8a). The T172A mutant possesses negligible basal and
AMP-stimulated activities, but importantly can be sensitized to
ADaM site metabolites/drugs through Ser108 phosphorylation13.
In α1/2-dKO iMEFs-expressing WT α2, phenformin, but not
A-769662, induced robust increases in pThr172 and pACC from
a high basal level. In cells expressing α2(T172A), phenformin and
A-769662, either alone or in combination, failed to induce
Thr172 phosphorylation as expected. Phenformin, but not
A-769662, induced a small increase in pACC from an undetect-
able basal level. Phenformin/A-769662 co-incubation resulted in
a further 5.8-fold increase in pACC compared to phenformin
alone, producing >30% the pACC signal in WT α2-expressing
cells treated with phenformin (Fig. 8a). Neither of these effects on
pACC were detected in α1/2-dKO iMEFs transduced with empty
lentivirus (Supplementary Fig. 6), conﬁrming that AMPK was the
only kinase phosphorylating ACC-Ser79 under these conditions.
A similar phosphorylation proﬁle was seen for Ser108 in α2
(T172A) cells, with phenformin inducing a small increase that
was ampliﬁed in the additional presence of A-769662 (Fig. 8b).
Phenformin/A-769662 co-incubation was the only condition that
induced a detectable increase in ULK1-Ser555 phosphorylation,
an AMPK substrate that is important for ULK1 activation32
(Fig. 8b).
Discussion
In this study, we demonstrate that β1-Ser108 in AMPK, a central
co-ordinator of energy homeostasis, is a phosphorylation target
for ULK1, a major regulator of autophagy initiation. Conse-
quently, ULK1 sensitizes AMPK to A-769662 and salicylate, the
active metabolic break-down product of acetylsalycilic acid
(aspirin), independently of Thr172 phosphorylation (Fig. 4d).
Salicylate stimulates fat utilization and reduces plasma fatty acids
in vivo15, reduces de novo lipogenesis in human hepatocytes and
MEFs33, 34, and reduces fatty acid and sterol synthesis in mac-
rophages35. Daily aspirin prophylaxis is also associated with
oncosuppression, an effect mirrored by the indirect AMPK acti-
vator metformin. Other β1-AMPK-speciﬁc direct activators
MT63-7836 and the indole acid derivative
PF-0640957737 have shown promise as treatments for either
prostate cancer or diabetic neuropathy, respectively. Although not
investigated, Ser108 phosphorylation is likely a requirement for
b
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AMPK activation by these compounds; MT63-78 shares common
structural features with A-769662, whereas the crystal structure of
PF-06409577 bound to the ADaM site contains the phosphomi-
metic residue Asp instead of Ser108. Our ﬁnding that ULK1
phosphorylates Ser108 is signiﬁcant given the emergence of this
modiﬁcation as a vital mechanistic constant for AMPK drugs.
Discovery of a mechanism that induces AMPK drug sensitization
independently of autophosphorylation also provides a potential
strategy to treat non-small-cell lung and cervical carcinomas,
associated with genetic loss of LKB138.
Accumulated evidence now depicts the ADaM site as an
“orphan” allosteric site for an unidentiﬁed endogenous AMPK
ligand: (i) β1-Ser108 and contacting α-residues are highly con-
served among eukaryotes; (ii) the β1-ADaM site is transient and
regulated; (iii) both ULK1 phosphorylation of Ser108, and acti-
vation of AMPK by small molecule drugs, share a common
speciﬁcity for the β1-isoform; (iv) synergistic activation of
unphosphorylated AMPK, orchestrated across all three AMPK
subunits and topographically distant β1-ADaM and γ-sites13,
appears a highly intrinsic activation mechanism. Additionally,
independent studies have described a disconnect between AMPK
signaling (using elevated pACC as an index) and apparent AMPK
activation (no increase in pThr172), most commonly in exam-
inations of the role of skeletal muscle AMPK during exercise39–42,
but also in response to reactive oxygen species (HeLa cells)43 and
berberine (LAMTOR1-KO MEFs)44. We now demonstrate that
signiﬁcant cellular AMPK signaling can be triggered indepen-
dently of pThr172 (Fig. 8a), although we are unable to determine
whether this arises exclusively by Ser108 phosphorylation,
AMP/drug synergistic activation of unphosphorylated enzyme, or
a combination of both.
Applying quantitative phosphoproteomics to investigate a
physiological role for Ser108 phosphorylation, we identiﬁed sig-
niﬁcant differences in the phosphorylation proﬁles of several cell
cycle-associated proteins in response to the phosphomimetic
mutant β1-S108E (Fig. 2). Our approach was limited in that we
do not know whether potential metabolite(s) acting at the S108E-
stabilized ADaM site were elevated in response to phenformin,
thus our ﬁndings are likely an underestimation of the global
effects of Ser108 phosphorylation. It should also be emphasized
that the differences reﬂect both primary and downstream phos-
phorylation events, so that the phosphosites detected encompass
more than direct AMPK sites. None of these phosphorylated
residues have been identiﬁed as direct AMPK substrates, however,
both DOCK7_Ser452 and NHRF1_Ser285 are potential candi-
dates based on consensus with the AMPK substrate recognition
motif (Supplementary Table 1). β1-S108E expression induced a
signiﬁcant increase in downstream phosphorylation of the PAK2
regulatory domain residue Ser141, an event required for full
kinase activity and subsequent induction of the cytostatic and
anti-apoptotic functions of full-length PAK245, 46. Other down-
stream targets are associated with regulation of cell cycle arrest
(Bin1; GO:0071156), p53-mediated cell cycle arrest (TB182;
GO:0006977) and cell division (CND1; GO:0051301). Although
functional roles for the majority of sites detected in our analysis
are unknown, our ﬁndings with PAK2 in particular point to a role
for β1-Ser108 phosphorylation in promoting energy stress-
induced pro-survival pathways over cell death pathways. This
model is consistent with other autophagy-inducing roles for
AMPK, and Ser108-phosphorylation as a direct mechanism to
activate AMPK by the autophagy initiator ULK1. Future studies
will delineate the cellular signaling mechanisms speciﬁc to
β1-Ser108 phosphorylation, and bridge the gap between AMPK
and the other identiﬁed downstream substrates.
Closer examination of our results from MEFs expressing only
α2(T172A) AMPK provides further insight into ULK regulation
of β1-AMPK signaling (Fig. 8). An integrated model, involving
positive and negative feedback loops, is shown in Fig. 9. AMPK
signaling in these cells is hampered by insensitivity to AMP;
consequently phenformin is unable to stimulate ULK1 activity,
contributing to the weak pSer108 response (Fig. 8b). Further
addition of A-769662 was sufﬁcient to rescue AMPK activity and
stimulate phosphorylation of ULK1-Ser555 and Ser108, poten-
tially via positive feedback. cis-autophosphorylation of Ser108 in
the α2(T172A) mutant is unlikely since activity of the unpho-
sphorylated complex can only be achieved synergistically; in the
AMP/drug-bound state Ser108 is presumably sequestered to the
ADaM site and away from the AMPK active site. The close
correlation between pACC, pSer108 and ULK-pSer555 proﬁles
across all conditions provides support for a positive feedback
mechanism between ULK and AMPK (Fig. 8a, b). Consistent with
this, co-incubation of cells expressing only KI-AMPK with
phenformin/A-769662 did not induce a further increase in
pSer108, compared to phenformin treatment alone (Fig. 3d). Our
model raises the intriguing prospect that, on ULK1-populated
membranes (autophagosome, mitochondria), AMPK may be
desensitized to AMP through suppression of α1-Thr172 phos-
phorylation, yet simultaneously sensitized to an alternate reg-
ulatory ligand through phosphorylation of β1-Ser108.
Initial attempts to examine trans-phosphorylation of Ser108 in
cells were confounded by strong background autopho-
sphorylation signals in HEK293T endogenous AMPK, and high
basal levels of pSer108 in immortalized MEFs (Fig. 6c). The cause
of elevated pSer108 in iMEFs is unknown. Since KI-AMPK was
not phosphorylated on Ser108 under basal conditions (Fig. 3d) we
expect loss of a pSer108 phosphatase activity, leading to accu-
mulation of Ser108 autophosphorylation in endogenous AMPK,
may be a contributing factor. We were able to exploit the intra-
molecular “limitation” of Ser108 cis-autophosphorylation by
using KI-AMPK in cells to uncouple background autopho-
sphorylation from input by alternate signaling pathways. We
identiﬁed conditions (glucose starvation, H2O2 and phenformin)
under which Ser108 is phosphorylated independently of AMPK
activity (Fig. 3b). These conditions also increase cellular LC3-II or
ULK1-pSer555, both standard markers for autophagic activity47–49.
Conﬁrmation of ULK1-mediated phosphorylation of Ser108 in
cells was provided by small molecule (Fig. 6a, b) or
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Fig. 9 An integrated model for ULK1 regulation of β1-AMPK signaling. The
initial ULK stimulus (e.g., Ser555 phosphorylation) is provided by AMPK,
activated itself in response to energy stress and elevated AMP:ATP. Once
activated, ULK1 suppresses Thr172 phosphorylation and AMPK sensitivity
to AMP via negative feedback (red arrows)20. ULK1 simultaneously
phosphorylates Ser108, sensitizing AMPK to drugs/metabolites acting at
the ADaM site. This would promote AMP-independent AMPK signaling
and maintain ULK1 activity via positive feedback (green arrows). In our cell
model, activity of α2(T172A) AMPK is not elevated in response to AMP and
requires additional stimulation with A-769662 to achieve ULK1
phosphorylation
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genetic (Fig. 6d) inhibition of ULK activity, each of
which resulted in almost complete loss of stress-induced Ser108
trans-phosphorylation.
ULK1 phosphorylation of Ser108 is speciﬁc to the AMPK
β1-isoform (Fig. 5); this is likely due to sequence heterogeneity
proximal to Ser108 in the β2-isoform that diverges from the ULK
consensus found in the corresponding β1 residues24. Interest-
ingly, β1 residues C-terminal to Ser108 (His109-Phe112) are
considered unfavorable for ULK substrates. However, Ser108 is
located at the end of a β-hairpin loop structure12 and
C-terminal residues may not participate in substrate recognition
by ULK1. β1-Ser108 does not appear to be a favorable substrate
for ULK2 (Fig. 4b, c), although we cannot rule out the possibility
that the two ULK2 preparations used in this study may have
possessed inherently low activity, given the current lack of
knowledge regarding cellular regulation and bona ﬁde substrates
for this kinase. Overall, our ﬁndings are in agreement with
autophagy network mapping showing interaction with AMPK β1
is restricted to ULK1, whereas ULK2 association is limited to
AMPK β241. Further investigation is warranted to determine
subsets of ULK1 and ULK2 downstream targets in vivo.
Our results here, and those of others, provide strong evidence
for potentiation of Ser108 phosphorylation by an AMP-myristoyl
switch mechanism, in which AMP-induced conformational
changes lead to ejection of the β-subunit myristoyl group from an
intramolecular-binding site3. The exposed myristoyl group pro-
motes AMPK targeting to intracellular membranes and, in this
case, ULK1 co-localization. Cell treatments that promote pSer108
independently of autophosphorylation (glucose starvation, H2O2
and phenformin) (Fig. 3b) are associated with increased AMP/
ATP ratio, either through mitochondrial toxicity or disruption of
ATP production50. Treatments that did not induce Ser108
phosphorylation activate AMPK independently of AMP (A-
769662, AICAR, ionomycin, amino-acid deprivation), or activate
ULK independently of changes in adenylate charge (mTOR
inhibitors) (Fig. 7a, c). The AMPK myristoyl-switching effect of
ZMP (the metabolized product of AICAR and an AMP mimetic)
has not yet been examined. Additionally, removal of either the
AMP-sensing ability of AMPK with γ1(D245A) mutation
(Fig. 7b), or β-subunit myristoylation with β1(G2A) mutation
(Fig. 7d), abrogated glucose starvation- and/or phenformin-
induced Ser108 phosphorylation. β1(G2A) mutation was pre-
viously shown to suppress AMPK partitioning to intracellular
membranes following glucose starvation3. ULK1 is also recruited
to membrane structures during autophagy initiation, notably the
autophagosome formation sites located near the ER51, and
mitochondria52. ULK activity is associated with recruitment of
other autophagy-associated proteins to the developing phago-
phore, including VPS34 and Beclin-1, both of which are phos-
phorylated by AMPK to achieve differential regulation of pro-
and nonautophagy pathways53. Finally, β-myristoylation is
strongly implicated in AMPK recruitment to LC3-containing
puncta in the LKB1-deﬁcient H23 human cancer cell line31.
Collectively, these studies point to a close association of AMPK
with ULK1 and the developing phagophore, and an important
role for the exposed AMPK myristoyl group (myr switch ON) in
targeting AMPK to phagophore membranes. A similar mechan-
ism has been proposed to control AXIN-mediated AMPK
recruitment to the late endosome/lysosome membrane for
Thr172 phosphorylation and AMPK activation by LKB130. An
unexpected ﬁnding was myristoyl-dependent suppression of
Ser108 phosphorylation by ULK1 in cell-free assays (Fig. 7e),
indicating that AMPK adopts a conformation in the myristoyl-
buried state (myr switch OFF) that is unfavorable for ULK1
phosphorylation of Ser108. Repression of Ser108 phosphorylation
was not alleviated by AMP; either this demonstrates a
requirement for myristoyl-group membrane embedment, or an
additional cellular component is required to derepress ULK
phosphorylation through myristoyl group sequestration. These
results may represent a protective mechanism to ensure Ser108
phosphorylation by ULK1 occurs exclusively at membrane
surfaces.
In summary, we have identiﬁed an additional layer of com-
munication between AMPK and ULK1, two major regulators of
cellular energy homeostasis. ULK1 phosphorylation of Ser108, a
post-translational modiﬁcation important for AMPK drug action,
may yield strategic opportunity to increase potency of AMPK-
targeting therapeutics. Differential phosphorylation of AMPK at
distinct cellular organelles/membranes raises the intriguing pos-
sibility of localized AMPK ligand sensitization. Myristoyl-
switching is a consistent driving force for both mechanisms;
whether secondary targeting signals are required to partition
distinct AMPK complexes between organelles represents an area
of great interest for the future.
Methods
Reagents. DNA oligos were from Sigma (Supplementary Table 3). Antibodies for
pan AMPK α (#2793, clone F6, 1:1000 dilution), FLAG (#2368, 1:1000 dilution),
myc (#2276, clone 9B11, 1:1000 dilution), HA (#2367, clone 6E2, 1:1000 dilution),
PAK1/2/3 (#2604, 1:1000 dilution), ULK1 (#4773, clone R600, 1:1000 dilution) and
tubulin (#3873, clone DM1A, 1:1000 dilution), and phosphospeciﬁc antibodies for
AMPK α-pThr172 (#2535, clone 40H9, 1:1000 dilution), AMPK β1-pSer108
(#4181, 1:1000 dilution), ACC-pSer79 (#3661, 1:1000 dilution), PAK1/2-pSer144/
Ser141 (#2606, 1:1000 dilution), ULK1-pSer555 (#5869, clone D1H4, 1:1000
dilution), and ULK1-pSer757 (#6888, 1:1000 dilution) were from Cell Signaling
Technology. AMPK-β1 antibody (#ab58175, 1:1000 dilution), A-769662
(#ab120335) and AICAR were from Abcam. IRDye 680RD- or 800CW-labeled
anti-immunoglobulin G antibodies (1:10,000 dilution) and IRDye 680RD-labeled
streptavidin (1:20,000 dilution) were from LI-COR Biosciences. Glutathione
Sepharose 4B and Streptavidin Sepharose high performance were from GE Life
Sciences. FLAG synthetic peptide (DYKDDDK) was provided by GL Biochem
(Shanghai). Other synthetic peptides were from Purar Chemicals. All peptides were
puriﬁed by reversed-phase chromatography and stored as lyophilized powder.
ULK2 recombinant protein was from Abcam. SBI-0206965, AZD8055 and INK128
were from ApexBio. FuGENE HD transfection reagent was from Promega Cor-
poration. All other reagents were from Sigma.
Cell culture. COS7 and HEK293T cell lines were purchased from American Type
Culture Collection. All cell lines were maintained in Dulbecco’s modiﬁed Essential
medium (DMEM) containing 10% fetal bovine serum and antibiotics (penicillin,
streptomycin) at 37 °C with 5% CO2. To generate iMEF cell lines, MEFs were
extracted from WT or homozygous AMPK β1β2 null embryos (days 12–14
post-coitum), generated by crossing homozygous β1 and β2 null mice54. WT and
AMPK β1/2 double knockout (β1/2-dKO) MEFs were immortalized by Fugene
HD-mediated transfection with an SV40 large-T antigen expression construct.
AMPK α1/2 double knockout (α1/2-dKO) and ULK1/2 double knockout
(ulk1/2-dKO) iMEFs were described previously23, 29.
Protein expression constructs. All mutants were generated using QuikChange
site-directed mutagenesis kits (Stratagene). All constructs were sequence veriﬁed.
Mammalian cell expression constructs were gifts from Reuben Shaw (pcDNA3
mouse FLAG-ULK1 (Addgene #27636) and pcDNA3 mouse FLAG-ULK2
(Addgene #27637)), Noboru Mizushima (pME18s-3xHA-human FIP200 (Addgene
#24303)) and Do-Hyung Kim (pRK5 human myc-Atg13 (Addgene #31965)). SV40
large-T antigen expression construct pBSSVD2005 was a gift from David Ron
(Addgene plasmid #21826). Complementary DNA (cDNAs) for human AMPK α1
or α2 were generated with N-terminal FLAG-tag and cloned into pcDNA3 using
XhoI/EcoRI (AMPK FLAG-α1) or XhoI/HindIII (AMPK FLAG-α2) restriction
sites. Lentivirus expression constructs LeGO-iG2, second generation viral packa-
ging vector psPax2 and ecotropic envelope vector pHCMV-EcoEnv were gifts from
Carl Walkley (St Vincent’s Institute of Medical Research). cDNAs for human
AMPK β1 (WT and mutants), α1 (WT and kinase inactive D141A mutant), and α2
(WT and T172A mutant) were generated with C-terminal FLAG-tag and cloned
into LeGO-iG2 using BamHI/NotI (β1) or EcoRI/NotI (α1 and α2) restriction sites.
Protein expression and puriﬁcation. Heterotrimeric human AMPK (α1β1γ1 and
α1β2γ1 expressed as N-terminal His6-α fusions; WT or mutants as indicated) was
expressed in E. coli strain Rosetta (DE3) and puriﬁed using nickel-Sepharose and
size exclusion chromatography as described previously13. Heterotrimeric human
AMPK (α1β1γ1 and α1β2γ1 expressed as an N-terminal GST-α fusion; WT or
mutants as indicated) was expressed in HEK293T cells as described previously3.
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Brieﬂy, HEK293T cells at 40% conﬂuency were triply transfected with expression
constructs for AMPK α-, β-, and γ-subunits, using transfection reagent FuGENE
HD according to the manufacturer’s protocols. Cells were harvested 48 h post-
transfection in ice cold lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl,
50 mM NaF, 1 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1% (v/v)
Triton X-100, protease inhibitors). Lysates were clariﬁed by centrifugation at
14,000 rpm for 5 min and ﬂash frozen in liquid N2 until processing. AMPK was
puriﬁed on glutathione Sepharose 4B and eluted in 50 mM Tris-HCl, (pH 7.4),
100 mM NaCl, 10% glycerol supplemented with 20 mM glutathione. ULK1/2 and
ULK1/FIP200/Atg13 complex was expressed by FuGENE HD transient transfec-
tion of HEK293T cells. Lysates were harvested after 48 h, clariﬁed by centrifugation
and ULK puriﬁed on anti-FLAG M2 afﬁnity gel. ULK was eluted in 50 mM
Tris-HCl (pH 7.4), 100 mM NaCl, 10% glycerol, 0.01% Tween-20 supplemented
with 1 mg/ml FLAG peptide. CaMKK2 isoform 1 was produced in Sf21 insect cells
as a C-terminal FLAG fusion as described previously3. Brieﬂy, Sf21 cells were
infected at a multiplicity of infection of 10 and harvested 72 h post-infection. Cell
lysates were prepared as for recombinant AMPK, and protein was puriﬁed on anti-
FLAG M2 afﬁnity gel. CaMKK2 was eluted in 50 mM Tris-HCl (pH 7.4), 100 mM
NaCl, 10% glycerol, 0.01% Tween-20 supplemented with 1 mg/ml FLAG peptide.
Lentiviral-mediated AMPK expression and puriﬁcation. Ecotropic lentivirus
was generated by transient transfection of HEK293T cells using calcium phosphate.
Brieﬂy, 1 day prior to transfection, 2–2.5 × 106 HEK293T cells were seeded per
10 cm culture dish. LeGO-iG2, psPax2 and pHCMV-EcoEnv plasmids (10 μg,
6.3 μg and 3.8 μg per 10 cm culture dish, respectively) were mixed together with
2M CaCl2 solution (244 mM ﬁnal concentration in 500 μl). The DNA/CaCl2
solution was added drop-wise, with vortexing, into 500 μl of 2xHEPES-buffered
saline, pH 7.06. After 20 min incubation at RT, the mixture was transferred drop-
wise onto HEK293T cell culture and incubated. Within 16 h of transfection, cell
were washed with phosphate-buffered saline (PBS) and replaced with 6 ml fresh
media. The lentivirus-containing supernatant was harvested after 48 and 72 h post-
transfection and stored at −80 °C.
iMEFs were transduced in 6-well plates by spinoculation. Brieﬂy, 1 day prior to
transduction, 0.5 × 105 cells per well in a 6-well plate were seeded in 2 ml media.
200 μl lentivirus supernatant in the presence of 8 μg/ml polybrene in 2 ml media
was spun for 98 min at 25 °C, 1100×g (Heraeus Megafuge 2.0 R). Lentivirus-
containing media was replaced with an equal volume of fresh media after 24 h.
Seventy-two hourspost-transduction, iMEFs were incubated with fresh media for 1
h and treated as indicated. Cells were harvested by washing with ice-cold PBS,
followed by rapid lysis in situ using 100 μl ice-cold lysis buffer (50 mM Tris.HCl
(pH 7.4), 150 mM NaCl, 50 mM NaF, 1 mM sodium pyrophosphate, 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol, 1% (v/v) Triton X-100 and protease inhibitors),
and cellular debris was removed by centrifugation.
FLAG-tagged AMPK α1 or α2, and acetyl-CoA carboxylase (ACC), were
isolated from iMEF cell lysates using anti-FLAG M2 afﬁnity gel or Streptavidin
Sepharose high performance, respectively. Immobilized ACC was washed
extensively with buffer A and eluted in 2×sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) loading sample buffer for immunoblotting.
Kinase activity assays. ULK and AMPK activities were determined by phos-
phorylation of a synthetic peptide (S108tide: KLPLTRSHNNFVARRR, corre-
sponding to AMPK β1(102–114) with three additional C-terminal Arg residues to
promote binding to P81 phosphocellulose paper) using 200 μM [γ-32P]ATP and
5mM MgCl2 in a 25 μl reaction volume at 30 °C. Reactions were terminated after
10 min by spotting 15 μl onto P81 phosphocellulose paper (Whatman) and
washing in 1% phosphoric acid. Radioactivity was quantiﬁed by scintillation
counting.
Kinase screen. Kinase screening (IKPT service) was performed by Kinexus,
Canada. S108tide (100 μM) was screened against a panel of 284 selected Ser/Thr
kinases with single replicate. Most assays were performed for 15 min duration,
50 μM [γ-33P]ATP, in a 25 μl reaction volume at 30 °C.
Generation of AMPK β2-pSer108 phosphospeciﬁc antibody. A phosphorylated
synthetic peptide (CSTKIPLIKpSHNDFVAILD, corresponding to AMPK β2
(100–117)) was coupled to keyhole limpet hemocyanin via the peptide N-terminal
cysteine residue using the coupling reagent N-succinimidyl-3(-2-pyridyldithio)
propionate. Rabbits were immunized with 2 mg of peptide conjugate initially in
50% (v/v) Freunds complete adjuvant and in 50% (v/v) Freunds incomplete
adjuvant for subsequent immunizations. Rabbits were boosted fortnightly with 2
mg of peptide conjugate and bled 7 days after booster injections. The pSer108
antibody was then puriﬁed from serum by peptide afﬁnity chromatography. Spe-
ciﬁcity for β2-pSer108 was evaluated by immunoblot against CaMKK2-
phosphorylated AMPK α1β2γ1, and α1β1γ1.
Immunoblotting. Samples were electrophoresed by 12% SDS-PAGE and trans-
ferred to Immobilon FL polyvinylidine-ﬂouride membrane (Millipore). The
membrane was blocked with 2% nonfat dry milk in PBS +0.1% Tween 20 (PBS-T)
for 1 h at room temperature. Membranes were incubated either overnight or for 1 h
with 1° antibodies (diluted 1:500–1:2000 in PBS-T), prior to 30 min incubation
with anti-rabbit or anti-mouse IgG 2° antibody ﬂuorescently labeled with IR680 or
IR800. Immunoreactive bands were visualized on an Odyssey membrane imaging
system (LI-COR Biosciences) and densitometry analyses performed using inte-
grated software. Uncropped western blot images associated with this study are
presented in Supplementary Fig. 7.
Quantitative global and phosphoproteomic analysis. β1/2-dKO iMEFs, trans-
duced with AMPK β1-S108A or β1-S108E, as described above, were incubated with
2 mM phenformin for 1 h. Treated lysates were acetone (−20 °C) precipitated and
resuspended in 8M urea/50 mM triethyl ammonium bicarbonate (TEAB) solution.
Protein lysates were reduced with 10 mM tris(2-carboxyethyl)phosphine (TCEP)
for 45 min at 37 °C, and alkylated with 55 mM iodoacetamide for 30 min at room
temperature in the dark. Samples were diluted to 1M urea in 25 mM TEAB and
trypsin (1:60, w/w) digested overnight at 37 °C. Digested tryptic peptides were
cleaned up using Oasis HLB (hydrophilic lipophilic balance) solid phase extraction
(SPE) cartridges (Waters) and freeze-dried overnight. Resuspended tryptic digests
were used for stable-isotope dimethyl labeling as described previously55. β1-S108A
and β1-S108E derived tryptic peptides were used for light and medium labeling,
respectively. Labeled peptides were mixed (1:1) and an aliquot (15 µl) was taken out
and run on liquid chromatography–mass spectrometry (LC-MS)/MS for total
proteome changes. Remaining mixed labeled peptides were SPE cleaned up and
freeze-dried before used for TiO2 phosphopeptides enrichment. Phosphopeptide
enrichment by TiO2 microcolumns was carried out as described previously56.
Mixed labeled peptides and TiO2 enriched phosphopeptides were analyzed by LC-
MS/MS using a Q-Exactive plus mass spectrometer (Thermo Scientiﬁc) ﬁtted with
nanoﬂow reversed-phase-high-performance liquid chromatography (HPLC)
(Ultimate 3000 RSLC, Dionex). The nano-LC system was equipped with an
Acclaim Pepmap nano-trap column (Dionex—C18, 100 Å, 75 μm× 2 cm) and an
Acclaim Pepmap RSLC analytical column (Dionex—C18, 100 Å, 75 μm× 50 cm).
Typically for each LC-MS/MS experiment, 5 μl of the peptide mix was loaded onto
the enrichment (trap) column at an isocratic ﬂow of 5 μl/min of 3% CH3CN
containing 0.1% formic acid for 6 min before the enrichment column is switched
in-line with the analytical column. The eluents used for the LC were 0.1% v/v
formic acid (solvent A) and 100% CH3CN/0.1% formic acid v/v (solvent B). The
gradient used was 3% B to 25% B for 23 min, 25% B to 40% B in 2 min, 40% B to
80% B in 2 min and maintained at 85% B for the ﬁnal 2 min before equilibration
for 9 min at 3% B prior to the next analysis. All spectra were acquired in positive
mode with full scan MS spectra scanning from m/z 375–1400 at 70,000 resolution
with AGC target of 3e6 with maximum accumulation time of 50 ms. Lockmass of
445.120024 was used. The 15 most intense peptide ions with charge states ≥2–5
were isolated with isolation window of 1.2m/z and fragmented with normalized
collision energy of 30 at 35,000 resolution with AGC target of 1e5 with maximum
accumulation time of 120 ms. Underﬁll threshold was set to 2% for triggering of
precursor for MS2. Dynamic exclusion was activated for 30 s. Mass spectrometric
raw data were processed and analyzed using Proteome Discoverer 2.1 (Thermo
Scientiﬁc) with Mascot search algorithm against mouse SwissProt database. Perseus
1.5.6.0 was used for further data analysis57. IPA software (QIAGEN Redwood City)
was used for network and pathway analysis.
In-gel digestion of protein bands and mass spectrometry. SDS-PAGE protein
bands were excised and simultaneously reduced and alkylated with 10 mM TCEP
and 40 mM 2-choloracetamide for 1 h at room temperature. Proteins were digested
with 13 ng/μl of sequencing grade trypsin (Promega) overnight at 37 °C and
peptides desalted using in-house made microC18 columns (3M empore). Peptides
were resuspended in 0.1% formic acid, 5% acetonitrile and analyzed on a Dionex
3500RS nanoUHPLC coupled to an Orbitrap Fusion mass spectrometer with Tune
v2.0.1258 in positive mode. Peptides were separated using an in-house packed
75 μm× 40 cm pulled column (1.9 μm particle size, C18AQ; Dr Maisch, Germany)
with a gradient of 2–30% acetonitrile containing 0.1% FA over 60 min at 250 nl/
min at 55 °C. An MS1 scan was acquired from 350–1550 (120,000 resolution, 5e5
AGC, 100 ms injection time) followed by MS/MS data-dependent acquisition with
HCD and detection in the Orbitrap (60,000 resolution, 2e5 AGC, 120 ms injection
time, 40 NCE, 2.0m/z quadrupole isolation width) and, EThcD and detection in
the orbitrap (60,000 resolution, 2e5 AGC, 120 ms injection time, calibrated charge-
dependent ETD reaction times [2 + 121; 3 + 54; 4 + 30; 5 + 20; 6 + 13; 7 + ; 10 ms],
25 NCE for HCD supplemental activation, 2.0m/z quadrupole isolation width). All
raw data were analyzed with MaxQuant v1.5.3.2558 and searched against the
human UniProt database with default settings including phosphorylation of S, T,
and Y as a variable modiﬁcation and match between runs enabled.
Nucleotide measurements. Adenine nucleotides from HEK293T perchlorate
extracts were measured by LC-MS on an ABISCIEX 5500 QTRAP mass
spectrometer16. AEC was calculated from ratios of [AMP], [ADP], and [ATP]
(Equation 1):
AEC ¼ ATP½  þ 0:5 ADP½ ð Þ
ATP½  þ ADP½  þ AMP½  ð1Þ
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Statistical analysis. The data are presented as mean values± s.e.m. of at least
three independent experiments. The unpaired two-tailed Student’s t-test was used
for all comparisons unless stated.
Data availability. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE59 partner repository with the
data set identiﬁer PXD006365. The authors declare that all other data supporting
the ﬁndings of this study are available within the paper and its Supplementary
Information ﬁles, or are available from the authors upon reasonable request.
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